Topical Psoriasis Composition Combining Antimitotic and Anti-inflammatory Agents
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for psoriasis often have low efficacy and significant side effects, with existing medications failing to provide an optimal solution for managing the condition effectively without adverse reactions.
Innovation Solution
A topical pharmaceutical composition combining 4,6-dimethyl-N-(3,4,5-trimethoxyphenyl)pyrimidin-2-amine and 2,4-O-(2-furanylmethylene)-1,3,5,6-tetra-O-methyl-D-glucitol, formulated with suitable excipients, which enhances therapeutic efficacy and reduces relapse periods without side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments (corticosteroids, tar, photochemotherapy) are used, then some therapeutic effect is achieved, but significant side effects occur
Solution Approach 1:
The patent combines two distinct compounds with different mechanisms of action: 4,6-dimethyl-N-(3,4,5-trimethoxyphenyl)pyrimidin-2-amine (antimitotic agent) and 2,4-O-(2-furanylmethylene)-1,3,5,6-tetra-O-methyl-D-glucitol (anti-inflammatory agent). This combination creates a synergistic effect that enhances therapeutic efficacy while reducing the need for high doses of individual agents, thereby minimizing side effects.
Solution Approach 2:
The invention creates a composite pharmaceutical formulation containing both compounds in specific proportions (0.1-10% w/w of compound I and 0.1-10% w/w of compound II). This composite approach allows the formulation to leverage the benefits of both agents simultaneously, achieving reliable therapeutic results without the severe side effects associated with conventional monotherapies.
2Reliability
If chemotherapeutic agents (cyclosporine A, methotrexate, retinoids) are used, then severe psoriasis is treated, but high liver toxicity occurs
Solution Approach 1:
The patent combines an antimitotic compound with moderate cytostatic action and a low-toxicity compound with anti-inflammatory properties. This combination provides effective treatment for severe psoriasis through synergistic action on different pathological pathways, while avoiding the high liver toxicity associated with conventional chemotherapeutic agents like cyclosporine A and methotrexate.
3Reliability
If biopharmaceuticals (monoclonal antibodies) are used, then good activity with low organ toxicity is achieved, but they are ineffective in obese individuals and inadvisable for patients with tumour history
Solution Approach 1:
The patent creates a topical formulation with dual mechanisms of action that can be universally applied across different patient populations. The combination of antimitotic and anti-inflammatory compounds addresses multiple aspects of psoriasis pathology, making the treatment effective and safe for obese individuals and patients with tumour history, whereas biopharmaceuticals have specific contraindications for these groups.
4Reliability
If single compound treatments are used, then treatment is simple, but efficacy is insufficient for optimal psoriasis management
Solution Approach 1:
The patent merges two compounds with complementary mechanisms of action into a single topical formulation, achieving synergistic therapeutic effects that are superior to either compound alone. The formulation maintains relative simplicity by combining agents that work through different pathways, addressing both cell proliferation and inflammation, thereby optimizing efficacy without excessive complexity.
Data Source
AI summary
Pharmaceutical compositions for topical administration for the treatment of psoriasis are described, containing as active ingredient therapeutically effective quantities of 4,6-dimethyl-N-(3,4,5-trimethoxyphenyl)pyrimidin-2-amine (I) and 2,4-O-(2-furanylmethylene)-1,3,5,6-tetra-O-methyl-D-glucitol combined with suitable excipients and/or diluents.